Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NYLIA 1/35 vs ESTROSTEP 21
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive consisting of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial lining.
Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.
Prevention of pregnancy,Oral contraceptive
Prevention of pregnancy,Treatment of moderate acne vulgaris in females >= 15 years of age who have achieved menarche, are not pregnant, and desire oral contraception
One tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no medication. Continuous sequential regimen.
One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.
Norethindrone: 5-14 hours (mean ~8 hours); Ethinyl estradiol: 7-36 hours (mean ~14 hours). Clinically, steady-state is achieved within 5-7 days.
Ethinyl estradiol: 13-27 hours (terminal); norethindrone acetate: 5-14 hours (terminal). Steady-state achieved within 3-5 days.
Ethinyl estradiol is metabolized primarily via CYP3A4; norethindrone is metabolized via reduction and glucuronidation, with some involvement of CYP3A4.
Ethinyl estradiol is metabolized primarily via CYP3A4 and undergoes glucuronidation and sulfation. Norethindrone acetate is deacetylated to norethindrone, which is metabolized by CYP3A4 and other CYP enzymes, and undergoes reduction and glucuronidation.
Renal: 40-60% (as metabolites, mainly ethinyl estradiol glucuronide and sulfate conjugates and norethindrone metabolites). Biliary/fecal: 30-50% (as conjugates and metabolites).
Biliary/fecal (40-50% as metabolites) and renal (30-40% as glucuronide and sulfate conjugates)
Norethindrone: 80-95% (mainly to SHBG and albumin). Ethinyl estradiol: 98-99% (mainly to albumin, induces SHBG synthesis).
Ethinyl estradiol: 97-98% bound to albumin; norethindrone: 95-97% bound to albumin and SHBG.
Norethindrone: ~4 L/kg (large Vd indicates extensive tissue distribution). Ethinyl estradiol: ~3 L/kg (distributes to breast, uterine, and hepatic tissues).
Ethinyl estradiol: 2.5-4.5 L/kg; norethindrone: 3.5-5.5 L/kg. Indicates extensive tissue distribution.
Oral bioavailability: Norethindrone ~60-70% (due to first-pass metabolism); Ethinyl estradiol ~50-60% (susceptible to CYP3A4-induced metabolism).
Ethinyl estradiol: 38-48% (oral, first-pass metabolism); norethindrone acetate: 50-70% (oral, deacetylation to norethindrone).
No specific dose adjustment recommended; use with caution in patients with renal impairment as limited data available.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution; no specific dose adjustment recommended.
Contraindicated in acute hepatitis, severe cirrhosis, benign or malignant liver tumors, or Child-Pugh class C cirrhosis. Use with caution in Child-Pugh class A or B; consider alternative therapy.
Use only after menarche; same dosing as adults (one tablet daily for 21 days, then 7 days off). Not indicated for premenarchal patients.
Not indicated for use before menarche. Post-menarche: same dosing as adults; use lowest effective dose for shortest duration.
Not typically used in postmenopausal women; no safety and efficacy established in geriatric population. Contraindicated in women over 35 who smoke heavily (≥15 cigarettes/day).
Not indicated for postmenopausal women; no established dosing in elderly. Consider alternative therapies as necessary.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and heavy smoking (≥15 cigarettes/day) and is most significant in women over 35 years. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women > 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction): discontinue if signs/symptoms occur,Cigarette smoking increases risk of serious cardiovascular events,Increased risk of gallbladder disease,Hepatic neoplasia (benign and malignant) – discontinue if jaundice or liver abnormalities develop,Hypertension – monitor blood pressure,Glucose intolerance – monitor in diabetic patients,Headache/migraine – discontinue if new or worsening,Bleeding irregularities (breakthrough bleeding, amenorrhea),Depression – discontinue if severe
Increased risk of thromboembolic disorders (e.g., venous thromboembolism, stroke, myocardial infarction), especially in smokers and women over 35,Hepatic neoplasia (benign and malignant) reported,Hypertension and gallbladder disease,Carbohydrate and lipid effects; monitor in diabetic patients,Ocular lesions (e.g., retinal thrombosis); discontinue if unexplained vision loss or proptosis occurs,Hereditary angioedema exacerbation,Chloasma; avoid sun exposure,Menstrual irregularities (e.g., breakthrough bleeding, amenorrhea),Depression; discontinue if severe
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Pregnancy (known or suspected),Hepatic adenoma or carcinoma (current or history),Jaundice or liver disease with impaired function (acute or chronic),Hypersensitivity to any component of the product
Thrombophlebitis, thromboembolic disorders, or history thereof (e.g., deep vein thrombosis, pulmonary embolism),Cerebrovascular disease (e.g., stroke, TIA),Coronary artery disease (e.g., myocardial infarction, angina),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Benign or malignant liver tumors,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35 years of age
Grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. High-fat meals may delay absorption of norethindrone/ethinyl estradiol but do not reduce overall efficacy. No specific food restrictions; may be taken with or without food. However, consistent timing is more important than with meals.
No specific food interactions. Grapefruit juice may increase estrogen exposure (mild effect). Maintain consistent timing with meals to reduce nausea if needed. Avoid alcohol if liver function is compromised.
FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects due to progestin/estrogen exposure. Second and third trimesters: Risk of masculinization of female fetuses (progestin-induced pseudohermaphroditism) and potential for estrogen-related adverse effects; contraindicated in pregnancy.
Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and neural tube defects. Second and third trimesters: associated with fetal genital abnormalities, feminization of male fetuses, and potential long-term reproductive effects. Use in early pregnancy for emergency contraception is not recommended due to potential risks.
Norethindrone/ethinyl estradiol passes into breast milk; M/P ratio not established. May reduce milk production and alter composition. Use during breastfeeding not recommended; consider using progestin-only contraceptives if needed.
Estrostep 21 is excreted in breast milk in small amounts; ethinyl estradiol M/P ratio approximately 0.1; norethindrone M/P ratio ~0.5. May reduce milk production and quality, especially in early lactation. Use generally avoided during breastfeeding; consider progestin-only alternatives.
Contraindicated in pregnancy; no dose adjustments applicable as therapy should be discontinued immediately upon pregnancy confirmation.
Estrostep 21 is contraindicated in pregnancy; no dose adjustments recommended as use is avoided. Pharmacokinetic changes during pregnancy (increased hepatic metabolism, volume of distribution) would require dose adjustment if used, but due to risks, alternative therapy is indicated.
Norethindrone/ethinyl estradiol (1 mg/35 mcg) is a monophasic combination oral contraceptive. It works primarily by suppressing ovulation. The 35 mcg ethinyl estradiol dose is standard; however, patients with estrogen-sensitive conditions (e.g., migraine with aura, history of thromboembolism) should avoid use. Advise patients to take at the same time daily to maintain efficacy. Missed pill management: if missed >24 hours, take missed pill as soon as remembered and use backup contraception for 7 days. Drug interactions: rifampin, certain anticonvulsants (phenytoin, carbamazepine), and some antibiotics (e.g., ampicillin, tetracyclines) may reduce contraceptive efficacy.
ESTROSTEP 21 is a monophasic oral contraceptive containing norethindrone acetate and ethinyl estradiol. Due to its low estrogen dose (20 mcg), it may be associated with more breakthrough bleeding compared to higher-dose pills. It is indicated for contraception and may be used for acne treatment. The 21-day regimen requires a 7-day hormone-free interval. Counsel patients that smoking increases the risk of serious cardiovascular adverse effects; avoid in women over 35 who smoke.
Take one tablet daily at the same time, even if you do not have sex. Missing pills increases pregnancy risk.,If you miss a pill by less than 24 hours, take it as soon as you remember. If more than 24 hours, take the missed pill and use backup contraception (e.g., condoms) for 7 days.,You may experience spotting or nausea during the first few packs; this usually improves.,Smoking increases the risk of serious cardiovascular side effects (blood clots, stroke, heart attack), especially if you are over 35. Do not smoke while taking this medication.,Contact your healthcare provider if you experience severe leg pain/swelling, chest pain, shortness of breath, severe headache, or vision changes.,This medication does not protect against sexually transmitted infections (STIs). Use condoms for STI prevention.,Some medications (e.g., rifampin, certain seizure or HIV medicines) can make birth control pills less effective; inform your healthcare provider of all medications you take.
Take one tablet daily at the same time each day for 21 days, then no pills for 7 days.,If you miss a dose, follow the package instructions; use backup contraception if missed more than one tablet.,Do not smoke while taking this medication; smoking increases risk of blood clots, stroke, and heart attack, especially if over 35.,Common side effects include spotting, nausea, breast tenderness, and headache; these often improve after a few cycles.,Seek emergency care if you have signs of a blood clot: sudden leg pain, chest pain, shortness of breath, or vision changes.,This medication does not protect against HIV or other sexually transmitted infections.,Take missed pills as soon as remembered; do not take more than two tablets in one day.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NYLIA 1/35 vs ESTROSTEP 21, answered by our medical review team.
NYLIA 1/35 is a Combined Oral Contraceptive that works by Combination oral contraceptive consisting of norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release, increases viscosity of cervical mucus to impede sperm penetration, and alters endometrial lining.. ESTROSTEP 21 is a Combined Oral Contraceptive that works by Estrostep 21 is a combination oral contraceptive containing ethinyl estradiol and norethindrone acetate. It works primarily by suppressing gonadotropin-releasing hormone (Gn RH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary, thereby inhibiting ovulation. Additionally, it thickens cervical mucus to impede sperm penetration and alters the endometrium to reduce implantation likelihood.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NYLIA 1/35 and ESTROSTEP 21 depend on the specific clinical indication. These are both Combined Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NYLIA 1/35 is: One tablet (norethindrone 1 mg/ethinyl estradiol 35 mcg) orally once daily for 21 days, followed by 7 days of placebo or no medication. Continuous sequential regimen.. The standard adult dose of ESTROSTEP 21 is: One tablet orally once daily for 21 days, each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NYLIA 1/35 and ESTROSTEP 21 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NYLIA 1/35 is classified as Category C. FDA Pregnancy Category X. First trimester: Increased risk of neural tube defects, congenital heart defects, and limb reduction defects due to progestin/estrogen exposure. Second an. ESTROSTEP 21 is classified as Category C. Estrostep 21 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: increased risk of cardiovascular malformations, limb reduction defects, and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.